GENB · Generate Biomedicines, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · GENB
Income Statement
| Line item | Q1 '26 |
|---|---|
| Revenue | $8.82M |
| Cost of Revenue | - |
| Gross Profit | - |
| R&D | $46.83M |
| SG&A | $10.15M |
| Total Operating Expenses | $56.97M |
| D&A | $3.41M |
| Operating Income | ($48.15M) |
| Interest Expense | $368.0K |
| Income Tax | $56.0K |
| Net Income | ($41.69M) |
| EPS - Basic | ($1.62) |
| EPS - Diluted | ($1.62) |
Balance Sheet
| Line item | Q1 '26 |
|---|---|
| Cash & Equivalents | $220.61M |
| Accounts Receivable | - |
| Inventory | - |
| Accounts Payable | $3.84M |
| Current Assets | $234.37M |
| Total Assets | $330.18M |
| Current Liabilities | $82.20M |
| Long-term Debt | - |
| Total Liabilities | $141.55M |
| Stockholders' Equity | ($434.52M) |
| Retained Earnings | ($676.29M) |
Cash Flow
| Line item | Q1 '26 |
|---|---|
| Operating Cash Flow | ($53.18M) |
| Investing Cash Flow | $75.53M |
| Financing Cash Flow | $20.56M |
| CapEx | $751.0K |
| Free Cash Flow | ($53.93M) |
Ratios
| Metric | Q1 '26 |
|---|---|
| Profitability | |
| Gross margin | - |
| Operating margin | -546.1% |
| EBITDA margin | -507.4% |
| Net margin | -472.7% |
| Free cash flow margin | -611.6% |
| FCF / Net income | 1.29 |
| R&D / Revenue | 531.0% |
| SG&A / Revenue | 115.1% |
| Effective tax rate | - |
| Return on assets | -12.6% |
| Return on equity | 9.6% |
| Return on invested capital | - |
| Liquidity | |
| Current ratio | 2.85 |
| Quick ratio | 2.85 |
| Cash ratio | 2.68 |
| Leverage | |
| Debt / Equity | - |
| Debt / Assets | - |
| Debt / EBITDA | - |
| Interest coverage | -130.9x |
| Equity multiplier | -0.76 |
| Liabilities / Assets | 0.43 |
| Efficiency | |
| Asset turnover | 0.03 |
| Inventory turnover | - |
| Days sales outstanding | - |
| Days inventory outstanding | - |
| Days payable outstanding | - |
| Cash conversion cycle | - |
| Valuation | |
| P / E | - |
| P / B | - |
| P / S | - |
| EV / EBITDA | - |
| Growth | |
| Revenue growth (YoY) | - |
| Revenue CAGR (3y) | - |
| Revenue CAGR (5y) | - |
| Gross profit growth (YoY) | - |
| Operating income growth (YoY) | - |
| Net income growth (YoY) | - |
| EPS growth (YoY) | - |
| EPS CAGR (3y) | - |
| EPS CAGR (5y) | - |
| FCF growth (YoY) | - |
| FCF CAGR (5y) | - |
| Book value growth (YoY) | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Generate Biomedicines against the 5 most active filers in the same SIC group.